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Ourmicrobial inhabitants that form the human gutmicrobiome inﬂu-
ence many aspects of our physiology that were previously unrecognized.olecular and Cellular Biology,
N1G 2W1, Canada.
eop@queensu.ca (E.O. Petrof),
. This is an open access article underAs the gut microbiome has recently become acknowledged as a virtual
‘organ’ in human biology, many studies have associated problems of this
ecosystem with a growing number of both gastrointestinal (GI) and
non-GI disease states. Because gutmicrobial composition tends to remain
relatively temporally stable within a given individual, there is potential
for this ecosystem to be exploited both as a predictor of health-status
and a valuable target for therapeutic intervention (Faith et al., 2013). In
this review,wewill examine howour increased understanding of gutmi-
crobiota has led to a surge in microbiome-based therapeutics for human
medicine.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The human gut microbiome is the collection of microorganisms,
their gene products and corresponding physiological functions
found in the human GI tract (Gill et al., 2006). Much of our current
understanding of the bacterial composition of the human gut
microbiome has come from ‘omics-based’ survey initiatives such
as the Human Microbiome Project (Human Microbiome Project
Consortium, 2012). These studies have provided great insight into
gut microbial diversity, however, understanding of the function of
the microbiome has lagged behind. To appreciate how the gut
microbiome inﬂuences health, we must consider not only the com-
position of the microbiome but also microbe-microbe and host-
microbe interactions.
2.1. How Is a ‘Healthy’ Microbiome Deﬁned?
Our gut microbial inhabitants collectively provide a myriad of
beneﬁcial physiological functions; for example, production of vita-
mins and nutrients, regulation of metabolism, exclusion of patho-
gens, and maintenance of the immune system (Lozupone et al.,
2012). The average healthy adult colon contains a dense microbial
community of approximately 160 bacterial species (Qin et al.,
2010). Phylogenomic studies of stool samples, primarily from West-
ern populations, have shown that although gut microbial composi-
tion varies greatly between individuals there are general trends
among healthy adults. Bacteroidetes and Firmicutes are the most
prevalent bacterial phyla, while Actinobacteria and Proteobacteria
are also prominent members (Human Microbiome Project
Consortium, 2012). The large inter-individual variation in the ratios
of these representative phyla can be attributed to numerous inﬂu-
ences; a recent study found 69 factors that signiﬁcantly correlated
with overall microbiota compositional variation including medica-
tion/drug use, health-status, age, sex, lifestyle, host genetics, diet,
and animal exposure (Falony et al., 2016).
The functional proﬁle of the gut microbiome is more conserved
than the taxonomic composition (Qin et al., 2010). Multiple studies
have shown that the overall metabonomic (complex system associ-
ated metabolomic proﬁle) (Marchesi and Ravel, 2015) and genetic
capabilities of gut microbial ecosystems appear to be somewhat
consistent across healthy adults (Human Microbiome Project
Consortium, 2012; Qin et al., 2010; Turnbaugh et al., 2009). For ex-
ample, short-chain fatty acids (SCFAs), produced bymany gut micro-
bial species through fermentation, provide 10% of our daily energy
requirements, regulate host energy demands, intestinal epithelial
cell homeostasis, and immune function, and also support the growth
of the gut microbiota (Marchesi et al., 2015). Overall, a diverse mi-
crobial consortium displaying functional redundancy will preserve
and augment essential functions associated with gut homeostasis
(Rampelli et al., 2015).
2.2. Gut Microbial ‘Dysbiosis’?
Gut dysbiosis can be deﬁned as an imbalance in a microbial ecosys-
tem characterized by a shift in the composition or function of microbes,
which can result in pathogenesis (Fig. 1). Antibiotics, toxic compounds,
poor diet, medical interventions, and disease can cause disturbances to,
and potentially loss of diversity within the gut microbiota ecosystem
(Hell et al., 2013). Diet is a major modulator of the gut microbiota; in
the absence of dietary complex carbohydrates (the main substrates for
SCFA production), microbial metabolism will shift towards proteolytic
fermentation, which results in the generation of potentially toxic, pro-
inﬂammatory compounds such as amines, ammonia, phenols and sul-
ﬁdes (Vipperla and O'Keefe, 2016). Such compounds have been impli-
cated in gut dysbiosis and the development of colorectal cancer and
inﬂammatory bowel disease (IBD) (Vipperla and O'Keefe, 2016).However, deﬁning gut microbial dysbiosis is challenging because
of the compositional variability of the microbial ecosystem across
different individuals. Although currently there is no biomarker for
dysbiosis, recent work suggests that certain correlations may be-
come diagnostically useful. For example, low fecal chromogranin
A (CgA) concentrations, alongside higher microbial diversity and
functional richness has been found to associate with higher high-
density lipoprotein (HDL) concentrations (Zhernakova et al.,
2016).
3. Gut Dysbiosis in Clostridium difﬁcile Infection (CDI)
C. difﬁcile is an anaerobic, sporulating, bacterial pathogen that is the
etiological agent of CDI (Abt et al., 2016). CDI is a leading cause of nos-
ocomial, antibiotic-associated diarrhea and the disease pathology isme-
diated by bacterial secreted toxins (Abt et al., 2016). Under normal
circumstances, the resident gut microbiota are thought to facilitate col-
onization resistance against C. difﬁcile suppressing its pathogenic activ-
ity in the colon (Theriot et al., 2014). However, broad-spectrum
antibiotic use disrupts host-microbiota homeostasis by decreasing gut
microbiota abundance, diversity, community structure, and altering
metabonomic functional proﬁles (Dethlefsen et al., 2008; Perez-Cobas
et al., 2013a, 2013b; Theriot et al., 2016, 2014). Many studies have de-
scribed microbial taxonomic alterations in CDI patients (Table 1). In
general, the gut microbiota of CDI patients have reduced overall bacte-
rial diversity, characterized by increases in Proteobacteria with de-
creases in Firmicutes and Bacteroidetes phyla in comparison to
healthy subjects (Antharam et al., 2013; Chang et al., 2008; Fuentes et
al., 2014; Rea et al., 2012; Schubert et al., 2014; Shahinas et al., 2012).
However, taxonomic changes do not appear to be consistent between
distinct patient cohorts likely because of the large inter-individual vari-
ation in human gut microbiota (Girotra et al., 2016; Schubert et al.,
2014).
Metabonomic alterations as a result of antibiotic use are important
in the context of CDI (Theriot et al., 2014). As an example, primary
and secondary bile acids have markedly different effects on C. difﬁcile;
primary bile acids promote growth of this pathogen while secondary
bile acids are inhibitory. Thus, an antibiotic-induced perturbation that
reduces secondary bile acid production can promote CDI (Theriot et
al., 2016). In addition, mucosal carbohydrate concentrations, which
can increasewhen antibiotics are present, can promote C. difﬁcile expan-
sion (Ng et al., 2013).
The standard treatment for CDI ismetronidazole or oral vancomycin,
which kill C. difﬁcile, providing symptomatic relief and allowing restora-
tion of colonization resistance (Surawicz et al., 2013). However, in ap-
proximately 25–30% of cases, persistent C. difﬁcile (as endospores) or
introduction of a new strain can lead to disease recurrence, which is
more likely when there is incomplete recovery of the gut microbiota
(Cornely et al., 2012). Management of recurrent CDI (rCDI) is a major
clinical challenge; patients that are non-responsive to antimicrobial
therapy require alternative treatment options (Lapointe-Shaw et al.,
2016).
4. Gut Dysbiosis in Ulcerative Colitis (UC)
UC, a form of IBD, is a chronic, relapsing, idiopathic, inﬂammatory
disorder of the colon and rectum (Bouma and Strober, 2003). In the
last decade, there have been increases in UC incidence and prevalence
worldwide, making it an important emerging global disease
(Molodecky et al., 2012). Although the pathogenesis of UC is complex,
multifactorial, and not fully understood, aberrant host immune re-
sponses, a dysfunctional intestinal barrier, and gut microbiota dysbiosis
have been associated with this condition (Lepage et al., 2011;Michail et
al., 2012).
Various studies have demonstrated a reduction of gut microbial di-
versity and taxonomic compositional differences in UC patients
Fig. 1.Alternative stable states (ball and cupmodel) of human gutmicrobial ecosystems. Herewe conceptualize the ecological stability of the human gutmicrobiota as inferred through its
species richness. The gut microbial ecosystem is represented as a ball that exists within an equilibrium represented as a cup. The depth of each cup is symbolic of the resilience of a given
ecosystem and is related to species richness, where lower diversity leads to lower resilience and the greater the likelihood that the “ball” will roll out of the “cup” into a new state of
equilibrium that may be less stable that the ﬁrst. Perturbational stresses caused by numerous factors such as poor diet, disease state, drug use (including antimicrobials),
immunosenescence as examples can impact bacterial diversity and force the ecosystem into a less-stable equilibrium state. Repeated stresses can cause a situation where function may
be reduced to the point that dysbiosis and the development of disease ensue.
Adapted from (Relman, 2012) and (Folke et al., 2004).
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are observed in taxonomic variation in comparison with CDI patients
(Table 1). Notably, UC has been associated with decreases in species
within the Lachnospiraceae family, and Faecalibacterium prausnitzii
(Lepage et al., 2011; Rossen et al., 2015). As known butyrate pro-
ducers, their reduction may account for the depletion of this SCFA
observed in some UC patients (Lepage et al., 2011). Additionally,
Akkermansia muciniphila, a commensal gut microbe that contributes
to the homeostatic balance of the intestinal mucus layer was found to
be reduced in UC patients (Png et al., 2010) potentially resulting in
decreased mucosal thickness corroborating histologic ﬁndings in
rectal biopsies from active UC patients (Pullan et al., 1994). Driven
by observations of gut microbial dysbiosis in UC, there is interest in
the development and application of microbiome-based therapeutics
for this indication.
5. Gut Dysbiosis in Obesity
Obesity is a severe worldwide public health issue that has
reached epidemic status in many industrialized countries
(Villanueva-Millan et al., 2015), and is deﬁned as the accumulation
of excess adipose tissue to the detriment of health (Boulange et al.,
2016) deﬁned as a body mass index (BMI) N 30 in adults. Dietary in-
take is a principal contributor to the pathophysiology of obesity,
however, gut microbes can modulate nutrient uptake and energy
regulation providing an important, albeit underexplored environ-
mental factor in metabolic syndrome and obesity-related disorders
(Boulange et al., 2016). The connection between obesity and the
gut microbiome is complicated by heterogeneity of patient diet, ge-
netics, age, lifestyle, hormones, and disease as well as the complexity
of clinical presentation of metabolic disorders (Boulange et al.,
2016).The gut microbiome has been implicated as an important player
in obesity following the seminal discovery that the ratio of
Firmicutes to Bacteroidetes (F:B), and energy harvest capacity differs
in obese versus lean animal and human subjects (Ley et al., 2006;
Turnbaugh et al., 2009). However, other studies of this link have pro-
vided conﬂicting results (Duncan et al., 2008; Fernandes et al., 2014;
Schwiertz et al., 2010), thus, currently, there is no consensus of the
importance of the F:B ratio as an indicator of obesity. In spite of
this, many groups have found that both obese animal and human
subjects have an altered gut microbiota compared to their lean coun-
terparts characterized by reduced bacterial diversity, and altered co-
lonic fermentation potential (Fernandes et al., 2014; Le Chatelier et
al., 2013; Schwiertz et al., 2010; Teixeira et al., 2013; Vrieze et al.,
2012) (Table 1). Metagenomically, the gut microbiome can be classi-
ﬁed into two groups: high gene count (HGC) or low gene count
(LGC). The HGC group, most often seen in lean individuals, was asso-
ciated with increased F. prausnitzii and butyrate (SCFA) levels, while
the LGC group, most often seen in obese individuals, was associated
with lower butyrate production, but higher levels of Bacteroides
spp. and Ruminococcus gnavus and more genes putatively associated
with pro-carcinogenic metabolite production and oxidative stress
(Le Chatelier et al., 2013). Diet-induced weight loss interventions
in the LGC group could partially restore these metabolic changes, il-
lustrating the plasticity of the gutmicrobiome and the signiﬁcant im-
pact of diet in obesity-related diseases (Cotillard et al., 2013).
6. Modulation of the Gut Microbiome Using Stool-based Therapeutics
In Table 2, we list representative examples of livemicrobial prepara-
tions and microbial-based products that are currently being developed
with therapeutic manipulation of the gut microbiome or its associated
host interactions in mind. Fecal-microbiota derived products, probiotic,
Table 1
Microbial taxa positively correlated to select gut conditions in human subjects.
Condition Study size/details Microbial taxonomic changes associated with conditiona Reference
CDI Fecal samples from n = 14 recurrent CDI patients (4 within this
group given FMT)
↑ Proteobacteria, ↓ Bacteroidetes,
↓ Firmicutes
Weingarden et al.,
2015
Fecal samples from n = 94 CDI, and n = 89 non-CDI inpatients ↑ Proteobacteria, ↓ Firmicutes (except Enterococcus and
Erysipelotrichia and some Lachnospiraceae)
Schubert et al., 2014
Fecal samples from n = 9 recurrent CDI patients given FMT in van
Nood et al. (2013) study
↑ Proteobacteria, ↑ Bacilli,
↓ Bacteroidetes, ↓ Firmicutes,
↓ overall microbial diversity compared to post-FMT and healthy
donor samples
Fuentes et al., 2014
Fecal samples from n = 22 C. difﬁcile culture-positive elderly
subjects, and n = 252 healthy elderly subjects
↑ Proteobacteria, Firmicutes (↓ Enterococcaceae and ↑
Lactobacillaceae), ↓ overall microbial diversity
Rea et al., 2012
Fecal samples from n = 39 CDI patients, n = 36 C. difﬁcile-negative
nosocomial diarrhea patients, and n = 40 healthy control subjects
↓ Firmicutes, ↑ Proteobacteria,
↓Microbial diversity in both diarrheal groups compared to healthy
controls
Antharam et al., 2013
Stool samples from n = 6 CDI patients given FMT ↑ Proteobacteria, ↓ Bacteroidetes,
↓ Firmicutes (speciﬁcally Lachnospiraceae, ↓ overall microbial
diversity
Shahinas et al., 2012
UC Fecal samples from n = 15 UC patients and n = 15 control subjects ↓ Bacteroidetes, ↓ Firmicutes,
↓ overall microbial diversity
Rajilic-Stojanovic et
al., 2013
RCT on FMT for UC (58 fecal samples total from n = 34 UC patients,
and n = 24 healthy donors)
↓ Firmicutes, ↑ Proteobacteria
↑ Bacteroidetes, ↑ Bacilli, no change in bacterial diversity
Rossen et al., 2015
Sequencing completed on inﬂamed and non-inﬂamed mucosal
biopsies from n = 6 UC patients, and n = 5 healthy controls
↑ Bacteroidetes, ↓ Firmicutes Walker et al., 2011
Fecal samples from n = 36 active UC patients treated with FMT, and
n = 34 active UC patients given placebo
Reduced bacterial diversity, no information on phyla, but:
↓ Lachnospiraceae, ↓ Ruminococcus
Moayyedi et al., 2015
Sigmoid colon biopsies from n = 8 monozygotic twin pairs
discordant for UC, and n = 10 healthy individuals
↑ Actinobacteria, ↑ Proteobacteria
(↓ Bacteroidetes), no change in Firmicutes, ↓ Overall bacterial
diversity
Lepage et al., 2011
Obesity Gut microbial communities proﬁled from n = 31 monozygotic twin
pairs, and n = 23 dizygotic twin pairs generally concordant for
obesity or leanness
↓ Bacteroidetes, ↑ Actinobacteria, no change in Firmicutes Turnbaugh et al.,
2009
Stool samples from n = 2 lean, and n = 12 obese individuals ↓ Bacteroidetes, ↑ Firmicutes Ley et al., 2006
Stool samples from n = 1 normal-weight adolescent, and n = 1
obese adolescent
↓ Bacteroidetes, ↑ Firmicutes Ferrer et al., 2013
Collected fecal samples from n = 52 lean, and n = 42 overweight or
obese individuals
No change in Firmicutes to Bacteroidetes (F:B) ratio between lean
and obese groups
Fernandes et al.,
2014
Stool samples from n = 30 normal range, n = 35 overweight,
n = 33 obese (deﬁned by BMI)
↑ Bacteroidetes, no change in Firmicutes Schwiertz et al., 2010
Stool samples from n = 9 metabolic syndrome patients undergoing
allogenic gut microbiota (n = 9) from healthy lean individuals or
autologous FMT (n = 9)
↓ Overall bacterial diversity, and ↑ Bacteroidetes, ↓ Lachnospiraceae
in obese subjects compared to lean prior to FMT
Vrieze et al., 2012
Abbreviations: Body mass index (BMI); fecal microbiota transplantation (FMT); Clostridium difﬁcile infection (CDI); randomized controlled clinical trial (RCT); ulcerative colitis (UC).
a Phylum level taxonomic changes are listed unless otherwise described.
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variety of indications. In the following section, we speciﬁcally discuss
the use of complex stool-based therapeutics as the most commonly
used treatment modalities to date.
6.1. Fecal Microbiota Transplantation (FMT)
FMT aims to restore gut microbiota diversity by transferring feces
from a healthy donor to a sick patient. The therapy has been extensively
used in the treatment of rCDI with good success, likely because the do-
nated gut microbial ecosystem can replace the microbiota lost through
antibiotic use and thus suppress C. difﬁcile overgrowth, promoting pa-
tient recovery (Seekatz et al., 2014). Recent studies have demonstrated
effectiveness of FMT for clinical cure of rCDI around 90% (Agrawal et al.,
2016; Kelly et al., 2016; van Nood et al., 2013; Youngster et al., 2016,
2014). Failure of a ﬁrst FMT is strongly associated with previous history
of CDI-related hospitalization events, preexisting IBD, being an inpatient
while receiving FMT, or severe/complicated rCDI status (Fischer et al.,
2016; Khoruts et al., 2016).
Donor strains introduced into the GI tract via FMT durably colonize
and establish themselves alongside or in place of thepre-existingmicro-
biota (Li et al., 2016; Seekatz et al., 2014). In general, decreases in
Proteobacteria, and increases in Firmicutes and Bacteroidetes have
been widely observed in CDI patients following FMT (Fuentes et al.,2014; Hamilton et al., 2013; Kelly et al., 2016; Khoruts et al., 2010;
Seekatz et al., 2014; Shahinas et al., 2012; van Nood et al., 2013;
Weingarden et al., 2015) (see Table 1). Butyrate-producing bacteria,
mainly from Ruminococcaceae and Lachnospiraceae families, are de-
pleted in CDI (Antharam et al., 2013), and the observation that FMT
can restore SCFA production by the gut microbiota (Fuentes et al.,
2014) has encouraged the investigation of metabonomic changes in
the gut microbiome post-FMT. In one study it was shown that post-
FMT patient metabolome proﬁles shifted from their pre-treatment
state to closely resemble their donor metabolome counterparts
(Weingarden et al., 2014). Increased amounts of secondary bile acids
were found to be the main FMT-induced metabolic change, suggesting
that restoring bile acid composition with FMT may play an important
role in treating rCDI (Weingarden et al., 2014).
Given the success of treating rCDI with FMT, there has been great
interest in extending this treatment modality to other gut diseases,
notably UC (Table 2). However, while CDI clearly results from a sim-
ple breakdown in gut microbiota diversity, the underlying cause of
UC is as yet unknown but likely to be more complex in etiology
(Petrof and Khoruts, 2014). Data from individual case studies have
suggested that FMT may be of beneﬁt for UC, however there are
mixed results from RCTs. To date, FMT has been assessed as a novel
therapeutic for UC in two RCTs (Moayyedi et al., 2015; Rossen et al.,
2015). The ﬁrst study found that 24% of patients who received FMT
Table 2
Select gut microbiome-based therapies in clinical or pre-clinical testing.
Active agent Presumed mechanism of action Indication Research status Company/innovator Reference/clinical
trial identiﬁera
Stool Restoration of colonization resistance through FMT CDI
Non-proﬁt stool bank, screening,
and FMT product development
OpenBiome Kazerouni et al., 2015
Stool bank and screening Advancing Bio AdvancingBio, 2016
RBX2660 FMT-derived bacteria to restore gut microbiota CDI, IBD Phase II RCT complete for CDI Rebiotix Inc. NCT01925417
MET-1 33 strain deﬁned bacterial ecosystem that restores
colonization resistance
Recurrent CDI Proof-of-principle clinical study NuBiyota Petrof et al., 2013
SER-109
Puriﬁed bacterial spore-based ecological
formulation to restore gut microbiota after
antibiotic treatment
Recurrent CDI
Missed primary endpoint in phase
II RCT
Seres Therapeutics
Inc.
Khanna et al., 2016;
NCT02437487
SER-287 Mild-to-moderate UC Phase I RCT NCT02618187
VE-202 Oral formulation of live Clostridial bacteria that
restore immune system homeostasis (increase
regulatory T cells)
IBD Pre-clinical Vedanta Atarashi et al., 2013;
Furusawa et al., 2013
CBM588
Clostridium butyricum bacterial probiotic Pediatric AAD Phase II RCT Osel Inc. Seki et al., 2003
UC with pouchitis Phase II RCT Yasueda et al., 2016
Lactin-V Lactobacillus crispatus bacterial probiotic
Bacterial vaginosis Phase II RCT complete
NCT00635622;
Hemmerling et al.,
2010
Recurrent UTIs Phase II RCT complete NCT00305227;
Stapleton et al., 2011
Lactobacillus
plantarum
Probiotic to modulate the gut microbiome CVD and obesity Phase II RCT complete OptiBiotix Health
PLC
Patent #:
WO2015067948A1
CNDO-201 Trichuris suis ova, nonpathogenic helminth
probiotic to modulate immune system
Crohn's disease Missed primary endpoints in two
phase II RCTs
Fortress Biotech NCT01576471;
NCT01279577
Blautix Proprietary live bacterial therapeutic IBS Phase I RCT complete 4D Pharma
Research Ltd.
RNS Number: 4931E
Thetanix Anti-inﬂammatory protein derived from
Bacteroides thetaiotaomicron
Pediatrics Crohn's
disease
Phase I RCT NCT02704728; Eudract
2014-005666-29
SYN-004 Targeted molecule that degrades IV β-lactam
antibiotics speciﬁcally in gut to protect microbiome
CDI,
antibiotic-resistant
infections and AAD
Phase II RCT Synthetic Biologics
Inc.
NCT02563106
Avidocins Genetically modiﬁed R-type bacteriocins that have
speciﬁc antibacterial activity
CDI, foodborne
pathogens
Pre-clinical AvidBiotics Gebhart et al., 2015;
Scholl et al., 2012, 2009
AG014 Genetically modiﬁed Lactococcus lactis probiotic
strain that secretes anti-inﬂammatory factors
IBD Phase I RCT complete Intrexon Vandenbroucke et al.,
2010
SHP-01 Narrow-spectrum lysin (antimicrobial enzyme)
speciﬁcally targeting C. difﬁcile
Acute and recurrent
CDI
Pre-clinical Symbiotic Health Hirsch et al., 2015;
Wang et al., 2015
VT301 Genetically-engineered lactic acid bacterial
probiotic that produce elaﬁn to heal gut epithelial
lining
IBD Pre-clinical ViThera
Pharmaceuticals
Motta et al., 2011
SGM-1019 Small molecule inhibitor that modulates
host-microbiota interactions
IBD Phase I RCT complete Second Genome Ratner, 2015
NM504/505 Modulating the gut microbiome using prebiotics to
improve glucose tolerance and other metabolic
parameters
Metformin-intolerant
type 2 diabetes
Phase 0 RCT MicroBiome
Therapeutics
NCT01866462; Burton
et al., 2015
Abbreviations: Antibiotic-associated diarrhea (AAD); Clostridium difﬁcile infection (CDI); cardiovascular disease (CVD); fecal microbiota transplant (FMT); inﬂammatory bowel disease
(IBD); irritable bowel syndrome (IBS); randomized controlled clinical trial (RCT); ulcerative colitis (UC); urinary tract infection (UTI).
a Applicable clinical trial registry numbers or primary literature references are included where publicly available.
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identiﬁed that FMT patients had increased microbial diversity in com-
parison to patients given placebo. An interesting trend was noted in
that the majority of patients who went into remission after FMT re-
ceived stool from a single healthy donor, suggesting particular bene-
ﬁts of this donor's microbiota above others (Moayyedi et al., 2015).
Although the study did not reach its primary efﬁcacy endpoint, it
attained signiﬁcance for the end point of remission. Interestingly, a
greater success in inducing remission was seen in patients who had
been recently diagnosed with UC (within the year previous to treat-
ment) compared to patients with a longer history of disease (75%
vs. 18%), suggesting a temporal window when UC patients may be
more receptive to FMT (Moayyedi et al., 2015).
In contrast, Rossen et al. showed no statistically signiﬁcant differ-
ence in clinical remission between UC patients who received FMT
sourced fromhealthy donors or autologous FMT (their own fecal micro-
biota), and only 41% of patients who received donor FMT achievedclinical and endoscopic remission. The authors of this study carried
out a detailed assessment of the fecal microbiota taxonomic composi-
tion pre- and post-FMT and demonstrated that the microbial ecosys-
tems of patients who responded to FMT from a healthy donor
increased in the numbers of bacterial species from Clostridium clusters
IV, XIVa, XVIII while the amount of Bacteroidetes species was reduced
(Rossen et al., 2015).
UC has a complex etiology and it is not yet understood whether gut
microbial dysbiosis is a cause or effect of disease; this may underlie the
apparent range of outcomes after FMT. When treatment is successful in
inducing remission, the heterogeneity of patient, donor, and mode of
delivery complicate the understanding of which factors contribute to
optimal clinical resolution.
Overall, there have been a limited number of studies evaluating the
effectiveness of FMT for the treatment of obesity.Whenmicrobiota con-
tents were transferred from obese mice into lean germ-free mice, the
recipient mice showed an increase in adiposity compared to control
42 C. Carlucci et al. / EBioMedicine 13 (2016) 37–45animals (Turnbaugh et al., 2006). Similarly, the transfer of stool from
monozygotic or dizygotic twins discordant for obesity into ‘humanized’
germ-free mice resulted in increased adiposity and the transmission of
obesity-associatedmetabolic phenotypes (Ridaura et al., 2013). Because
the gutmicrobiota imparts such clear phenotypic changes to distinct re-
cipientmammalian hosts, this holds promise for the therapeuticmanip-
ulation of the microbiome to treat obesity-related disorders. There is
currently only one published report investigating the effects FMT has
on metabolic syndrome in human subjects. In this small RCT, FMT
from healthy lean donors to patients withmetabolic syndrome resulted
in increased insulin sensitivity 6 weeks after transfer (Vrieze et al.,
2012). This improvement was associated with increased gut microbial
diversity (including butyrate-producing bacteria, particularly Roseburia
intestinalis) (Vrieze et al., 2012). Butyrate is known to play an important
role in promoting insulin sensitivity in mice (Lin et al., 2012), thus it is
possible that an increase in butyrate production may be responsible
for the observed therapeutic effect of FMT (Vrieze et al., 2012). Further
studies investigating global compositional and metabolic changes
resulting from FMT are ongoing and will be necessary to bring
targeted-microbiome therapeutics into clinical practice.
6.2. Stool-substitute Therapies
Stool-substitute therapies aim to combine the high-effectiveness of
FMT with the excellent safety-proﬁle of probiotics to mitigate many of
the concerns of each respective therapeutic option. To date, this ap-
proach has been used only for the treatment of rCDI. Stool-substitute
therapies use deﬁned, standardized preparations of stool-derived prod-
ucts, while retaining the compositional, metabolic and transcriptomic
properties of fecal communities. Tvede and Rask-Madsen were among
the ﬁrst to use a stool-derived microbial consortium of 10 bacterial
strains to cure six patients with CDI (Tvede and Rask-Madsen, 1989).
However, at the time of the study, CDI was considered an uncommon
complication of antibiotic use and no real progress was made in the
ﬁeld for almost three decades.
In a small proof-of-principle trial we demonstrated a successful cure
of two rCDI patients, using a stool-substitute preparation of 33 puriﬁed
bacterial strains (MET-1)which had been derived from a single, healthy
donor (Petrof et al., 2013). As for FMT, the microbiota proﬁles of the
treated patients indicated incorporation of the MET-1 composition
strains after a single administration of the therapeutic. Signatures iden-
tifying with MET-1 strains were present in the patients 6 months post-
treatment, suggesting that a subset was able to colonize the recipients;
this setsMET-1 apart from conventional probiotics assessed to date, and
highlights the therapeutic potential representative of a multi-species
microbial ecosystem (Petrof et al., 2013). Seres Therapeutics Inc. has
also developed stool-substitute therapies for rCDI with a varied ap-
proach by using a spore-basedmicrobial ecosystem formulation. Results
from their ﬁrst RCT with product SER-109 were promising, however in-
terim results from their phase II RCT have been largely disappointing
(Seres Therapeutics Inc., 2016). In general, as with FMT, the utility of
stool-substitute therapies for treatment of rCDI requires further re-
search to understand, and capitalize upon, their mechanisms of action.
7. Regulation of Stool-based Therapeutics
There is persuasive evidence for the use of FMT in rCDI, and perhaps
also for a number of different diseases where the gut microbiota may
play a pivotal role. FMT is cost effective and now recommended for
treating rCDI nonresponsive to conventional antibiotic therapy (HQO,
2016; Lapointe-Shaw et al., 2016; Merlo et al., 2016). As such, two reg-
istered stool banks have emerged in the USA that screen and provide
FMT products for use in the treatment of rCDI (Kazerouni et al., 2015;
Advancing Bio, 2016) (Table 2). These organizations aim to facilitate
and expand FMT access, nonetheless, the FMT regulatory landscape
poses one of the biggest obstacles to efﬁcient delivery of FMT to rCDIpatients, as well as to the exploration of potential uses of FMT for
other diseases.
In many countries that recommend FMT for rCDI (e.g. England, Aus-
tria, Australia), FMT is not considered a drug by regulatory bodies
(GESA, 2015; Kumpet al., 2014; NICE, 2014). In contrast, Health Canada,
the Federal Drug Administration, (FDA, USA), and the Agence nationale
de sécurité du médicament, (ANSM, France) all classify FMT as a drug
(ANSM, 2014; FDA, 2013; Health Canada, 2015). Because fecal material
is extremely complex containing livingmicrobes,microbialmetabolites,
host cells, and food particles; it is not inert and thus cannot be standard-
ized as a drug in termsof pharmacokinetics, pharmacodynamics, or con-
sistency of chemical composition. Labeled as a drug, storage of FMT falls
under the jurisdiction of the pharmacist, which has caused problems for
implementing FMT in North America but perhaps more so in France,
where the preparation and documentation of FMT material is the re-
sponsibility of the pharmacist (Kump et al., 2014). Pharmacies not
equipped for preparation of FMT material must coordinate with a mi-
crobiology laboratory, adding an additional layer of complexity. In addi-
tion, for tracking purposes donor fecal samples must be stored for a
minimum of two years. Across regulatory bodies, there is also no clear
consensus on donor screening tests. The ANSM is the most speciﬁc, re-
quiring a two-step screening process and indicates which types of cul-
ture media and PCR tests should be employed (ANSM, 2014). Health
Canada provides less speciﬁc recommendations, suggesting a list of po-
tential pathogens for testing at the discretion of the treating physician
(Health Canada, 2015).
Currently the FDA will allow FMT for the treatment of rCDI without
the need for an Investigational New Drug (IND) application, provided
the donor and donor stool are adequately screened, and the health
care provider obtains adequate consent from the patient after discus-
sion of risks (FDA, 2013). An IND is required if the above conditions
are not met, and for FMT for any indication other than rCDI. Health Can-
ada has released similar restrictions (Health Canada, 2015). In March
2016, the FDA proposed an additional “enforcement discretion” clause
that requires the donor be “known” to the treating physician, i.e. that
the FMT product used is not obtained from a stool bank (IDSA, 2016).
These restrictions, while aimed at improving safety, create delays, as
healthy donors need to be sourced and screened. The FDA currently
continues to exercise “enforcement discretion”, however, the Infectious
Disease Society of America (IDSA) has recently requested that IND reg-
ulations for using FMT from stool banks to treat rCDI be waived, as they
may cause potentially fatal delays in providing treatment for rCDI (IDSA,
2016). IDSA also pointed out that stool banks very comprehensively
screen their donors. Indeed, the development of centralized, registered
stool banks, with rigorous donor screening and FMT processing proto-
cols in place, would be more efﬁcient overall.
Another issue raised by the IDSA and others is the urgent need to es-
tablish a national FMT registry in order to monitor safety and long-term
adverse events of FMT (Hecht et al., 2014; Vyas et al., 2015). Earlier this
year, the American Gastroenterological Association (AGA) received
funding from the National Institutes of Health (NIH) for creation of the
ﬁrst national registry for patients receiving FMT (AGA, 2016). The registry,
designed to assess efﬁcacy, patient outcomes and safety, aims to collect
data from over 4000 patients over a 10-year period and will begin pro-
spectively collecting clinical data starting in 2017. Such registries have
been established for other human tissue products (e.g. blood, semen,
breastmilk and organs). The FDA regulates each of these products differ-
ently, and the development of a newcategory of “tissue” for FMT, as advo-
cated by many (Vyas et al., 2015) would address most of the issues
surrounding standardization of the practice of FMT. Though regulatory
agencies have yet to adopt this stance for FMT, new knowledge obtained
from such a registry may provide valuable information in this regard.
This leaves us with the emerging approach of stool-substitute thera-
pies. Several groups are pursuing this avenue of research (Table 2) in the
hope of expediting the commercial availability of an effective FMT-like
treatment for rCDI that lacks many of its drawbacks.
43C. Carlucci et al. / EBioMedicine 13 (2016) 37–45Regulatory bodies acknowledge that their requirements are not per-
fect; their goal is to provide optimal safety conditions for the FMT recip-
ient based on the current state of knowledge on FMT, and they
recognize that more clinical trials and long-term outcome data are
needed. However, regulation must be carefully balanced with the fact
that stool is widely available, and overly restrictive policies will drive
patients to seek DIY approaches, easily found on the web, which can
be dangerous without appropriate medical oversight. As regulatory
bodies continue to grapple with the most appropriate way to regulate
FMT, either therewill need to be a change in regulations to better reﬂect
the complex nature of stool, or the ﬁeld will be forced tomovemore to-
wards developing deﬁned mixtures and away from FMT.8. Outstanding Questions
Given the potential of microbiome-based products for rCDI, there is
interest in examining whether stool-derived therapeutics will prove
beneﬁcial for other indications including inﬂammatory intestinal dis-
eases. As we continue to unravel the mechanisms behind the effective-
ness of stool-derived therapies for rCDI, many ﬁndings emphasize the
importance of a robust gut microbiota to host health. Investigating
whether suchmechanisms hold true for other GI and non-GI indications
are important future research directions to pursue. As FMT has been
adopted into clinical practice inmany countries, theproper standardiza-
tion of FMT across regulatory bodies, for example through the use of
standardized preparations, guidelines surrounding indication, and a
better deﬁnition of what is considered to be a healthy microbiota will
be necessary for efﬁcient, consistent and safe use of this treatment mo-
dality (Abt et al., 2016).9. Search Strategies and Selection Criteria
Data for this reviewwere identiﬁed by searches of PubMed, and ref-
erences from relevant articles using the search terms “gutmicrobiome”,
“gut microbiota”, “antibiotics”, “probiotics”, “fecal microbiota trans-
plant”, “clostridiumdifﬁcile”, “ulcerative colitis”, “obesity”. Unpublished
reportswere included in the FMT regulatory section. An exhaustiveweb
searchwas conducted to compile themicrobiome-based therapeutics in
pre-clinical or clinical testing described in Table 2.References
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